Kissei Pharmaceutical Co., Ltd. (TYO:4547)
3,855.00
-230.00 (-5.63%)
Aug 4, 2026, 9:04 AM JST
Kissei Pharmaceutical Revenue
Kissei Pharmaceutical had revenue of 23.39B JPY in the quarter ending June 30, 2026, with 5.40% growth. This brings the company's revenue in the last twelve months to 98.60B, up 10.35% year-over-year. In the fiscal year ending March 31, 2026, Kissei Pharmaceutical had annual revenue of 97.41B with 10.28% growth.
Revenue (ttm)
98.60B
Revenue Growth
+10.35%
P/S Ratio
1.62
Revenue / Employee
55.21M
Employees
1,786
Market Cap
159.80B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 97.41B | 9.08B | 10.28% |
| Mar 31, 2025 | 88.33B | 12.75B | 16.87% |
| Mar 31, 2024 | 75.58B | 8.09B | 11.98% |
| Mar 31, 2023 | 67.49B | 2.11B | 3.23% |
| Mar 31, 2022 | 65.38B | -3.66B | -5.31% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sumitomo Pharma | 474.79B |
| Towa Pharmaceutical | 273.71B |
| Sawai Group Holdings | 201.68B |
| Tsumura & Co. | 192.62B |
| Nippon Shinyaku | 170.77B |
| KYORIN Pharmaceutical | 125.68B |
| Mochida Pharmaceutical | 116.95B |
| Zeria Pharmaceutical | 89.16B |
Kissei Pharmaceutical News
- 3 days ago - Kissei Pharmaceutical Quarterly report: Q1 2027 - Filings
- 3 days ago - Kissei Pharmaceutical Slides: Q1 2027 - Filings
- 3 months ago - Kissei Pharmaceutical Quarterly report: Q4 2026 - Filings
- 3 months ago - Kissei Pharmaceutical Slides: Q4 2026 - Filings
- 6 months ago - Kissei Pharmaceutical Quarterly report: Q3 2026 - Filings
- 8 months ago - Kissei Pharmaceutical initiated with a Neutral at UBS - TheFly
- 9 months ago - Kissei Pharmaceutical Quarterly report: Q2 2026 - Filings
- 9 months ago - Kissei Pharmaceutical Slides: Q2 2026 - Filings